All data are based on the daily closing price as of March 28, 2025
p

PharmaEssentia

6446.TW
16.79 USD
-0.08
-0.47%

Overview

Last close
16.79 usd
Market cap
5.72B usd
52 week high
23.57 usd
52 week low
8.76 usd
Target price
21.11 usd

Valuation

P/E
62.4719
Forward P/E
N/A
Price/Sales
18.4665
Price/Book Value
6.5444
Enterprise Value
4.81B usd
EV/Revenue
16.4008
EV/EBITDA
47.1727

Key financials

Revenue TTM
293.31M usd
Gross Profit TTM
257.84M usd
EBITDA TTM
55.64M usd
Earnings per Share
0.27 usd
Dividend
N/A usd
Total assets
867.04M usd
Net debt
-583.77M usd

About

PharmaEssentia Corporation, a biopharmaceutical company engages in treatment for human diseases in Taiwan and internationally. Its products include Ropeginterferon alfa-2b that is used for the treatment of chronic myelogenous leukemia, T-Cell leukemia, early myelofibrosis, polycythemia vera, and essential thrombocythemia. The company also develops TCRT, anti PD-1, PEG-cytokine X,Y, and novel checkpoint abs for the treatment of solid tumors; P1101 + anti PD-1 for the treatment of hepatocellular carcinoma; and PEG-GCSF for the treatment of neutropenia. In addition, it focuses on the drug research and development programs in the areas of hematology, infectious disease, and oncology. PharmaEssentia Corporation was founded in 1990 and is headquartered in Taipei, Taiwan.
  • Symbol
    6446.TW
  • Exchange
    TW
  • Isin
    TW0006446008
  • Country
    Taiwan
  • Sector
    Healthcare
  • Industry
    Drug Manufacturers - Specialty & Generic
  • CEO
    Dr. Ching-Leou Teng Ph.D.
  • Headquarter
    Taipei
  • Web site
    https://www.pharmaessentia.com
Jakota Newsletter

Stay ahead in the JAKOTA stock markets with our roundup of vital insights

Icon scroll to top